Conference abstract · 31 Aug 2020
Short communicationPublished 18 May 2021
Stakeholders involved in vaccine purchasing and usage
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The vaccine segment is anticipated to be one of the fastest growing one of the healthcare industry and several leading firms have stepped up vaccine investments in recent years. Unlike therapeutic agents, vaccines are administered to healthy individuals only once or very infrequently during a life time. Vaccines generate well-documented positive externalities, yet their poor awareness and acceptability among vaccine end-users may contribute to resurgence of transmissible diseases and consequently trigger governmental interventions such as mandating vaccination. In addition to technical and clinical development per the highest quality standards, bringing new vaccines to market requires carefully orchestrated programs targeting the multiple types of stakeholders along the entire value chain and addressing their respective purchasing behavioral drivers. Against a backdrop of anti vaccination buzz and vaccine fatigue, successful global launch and sustainable usage of a vaccine requires the development of a multi pronged strategy addressing all aspects in relation to acceptability (e.g. the motivation to immunize despite the quasidisappearance of the disease), accessibility (e.g. supply chain services), availability (e.g. mechanisms ensuring reliability of supply) and affordability (e.g. tiered pricing policy taking country differences in per capita income into account). Leveraging novel technological advances can positively influence the ability to activate these levers successfully. A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight a disease that has already occurred, such as cancer)..
Keywords
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 6 Dec 2018
Novel technologies can successfully activate positive behaviors of stakeholders involved in vaccine purchasing and usage
Conference abstract · 9 Oct 2018
Successfully activating positive behaviors of the stakeholders involved in vaccine purchasing and usage through technological advances
Conference abstract
Successful activation of the behavioral drivers of the stakeholders involved in vaccine purchasing and usage
Conference abstract · 2019
SUCCESSFULLY ACTIVATING POSITIVE BEHAVIORS OF THE STAKEHOLDERS INVOLVED IN VACCINE PURCHASING AND USAGE THROUGH TECHNOLOGICAL ADVANCES
More from this journal
The newest in Current research in Virology & Retrovirology.
Commentary · 31 Jan 2022
Organisms and Beneficial Microbes
Opinion · 31 Jan 2022
Bacteria and Microbiology
Opinion · 29 Jan 2022
Virology, Emerging Diseases & Vaccines
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCurrent research in Virology & Retrovirology
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Pierre A Morgon”

